<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02229994</url>
  </required_header>
  <id_info>
    <org_study_id>2009-A00181-56</org_study_id>
    <nct_id>NCT02229994</nct_id>
  </id_info>
  <brief_title>Development of a New Tool for Dyspnea Measurement in Chronic Respiratory Diseases</brief_title>
  <acronym>DYSLIM</acronym>
  <official_title>Development of a New Tool for Dyspnea Measurement (DYSLIM for Dyspnea Limitation) in Chronic Respiratory Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pr Joel COSTE, Hôpital Hôtel Dieu - Unité de Bio Statistiques et Epidémiologiques, Paris</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is the psychometric validation of a self-administered dyspnea&#xD;
      questionnaire, usable in clinical practice in order to assess dyspnea and its impact on&#xD;
      patients with chronic respiratory diseases.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dyspnea is a cardinal Respiratory symptom.&#xD;
&#xD;
      According to the ATS dyspnea is the term used to characterize a subjective experience of&#xD;
      breathing discomfort, covering qualitatively distinct sensations of varying intensity.&#xD;
&#xD;
      The subjective nature of dyspnea and the high complexity of its determinants explain the&#xD;
      often moderate correlations obtained with physiological data. Dyspnea must therefore be&#xD;
      measured specifically.&#xD;
&#xD;
      The aim of this study is the cross-sectional and longitudinal psychometric validation of a&#xD;
      self-administered dyspnea questionnaire (assessing the impact of dyspnea on activities&#xD;
      restriction), usable in clinical practice in order to assess dyspnea and its alterations in&#xD;
      adult patients with chronic respiratory diseases.&#xD;
&#xD;
      (COPD, diffuse interstitial lung diseases, Pulmonary arterial hypertension, Cystic fibrosis)&#xD;
&#xD;
      Like any psychometric instrument, an efficient evaluation of dyspnea scale should ideally&#xD;
      satisfy all the following required features: evaluative, discriminant, good reproducibility,&#xD;
      and high sensitivity to change.&#xD;
&#xD;
      The desired features apart from content validity are reproducibility and especially a high&#xD;
      sensitivity to change, particularly following pulmonary rehabilitation.&#xD;
&#xD;
      Thus, this questionnaire should precisely enable to assess the benefit of rehabilitation and&#xD;
      it's sustainment in maintenance phase.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 16, 2010</start_date>
  <completion_date type="Actual">December 30, 2015</completion_date>
  <primary_completion_date type="Actual">March 27, 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Psychometric validity of the questionnaire</measure>
    <time_frame>Until end of treatment (making a total of 6 months)</time_frame>
    <description>Cross-sectional and longitudinal psychometric validation of a self-administered dyspnea questionnaire</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Analysis of responses distribution</measure>
    <time_frame>Until end of treatment (making a total of 6 months)</time_frame>
    <description>Cross-sectional and longitudinal data to assess the psychometric validity of a self-administered dyspnea questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Structural analysis (in principal components)</measure>
    <time_frame>Until end of treatment (making a total of 6 months)</time_frame>
    <description>Cross-sectional and longitudinal data to assess the psychometric validity of a self-administered dyspnea questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>External and convergent validity</measure>
    <time_frame>Until end of treatment (making a total of 6 months)</time_frame>
    <description>Cross-sectional and longitudinal data to assess the psychometric validity of a self-administered dyspnea questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Internal coherence</measure>
    <time_frame>Until end of treatment (making a total of 6 months)</time_frame>
    <description>Cross-sectional and longitudinal data to assess the psychometric validity of a self-administered dyspnea questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reproducibility</measure>
    <time_frame>Until end of treatment (making a total of 6 months)</time_frame>
    <description>Cross-sectional and longitudinal data to assess the psychometric validity of a self-administered dyspnea questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reproducibility</measure>
    <time_frame>7 days</time_frame>
    <description>for a sub sample of 50 patients, Cross-sectional and longitudinal data to assess the psychometric validity of a self-administered dyspnea questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Discriminating properties</measure>
    <time_frame>Until end of treatment (making a total of 6 months)</time_frame>
    <description>Cross-sectional and longitudinal data to assess the psychometric validity of a self-administered dyspnea questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Derivation of a scoring algorithm</measure>
    <time_frame>Until end of treatment (making a total of 6 months)</time_frame>
    <description>Cross-sectional and longitudinal data to assess the psychometric validity of a self-administered dyspnea questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensitivity to change</measure>
    <time_frame>Until end of treatment (making a total of 6 months)</time_frame>
    <description>Sensitivity to change will be analyzed in relation to:&#xD;
The TDI score, at the Likert scale on changes in dyspnea The scores of quality of life with their respective significant thresholds A the overall medical evaluation A changing EFR parameters with their respective significant thresholds (FEV, DLCO, walk test .....).&#xD;
All this are the transversal data necessaries to assess the validation of a psychometric self-administered dyspnea questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimal difference clinically relevant</measure>
    <time_frame>Until end of treatment (making a total of 6 months)</time_frame>
    <description>Cross-sectional data necessary to assess the psychometric validity of a self-administered dyspnea questionnaire</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">199</enrollment>
  <condition>COPD (With - Without Rehabilitation)</condition>
  <condition>Diffuse Interstitial Lung Diseases</condition>
  <condition>Pulmonary Arterial Hypertension Primary or Secondary (Post Embolic .....)</condition>
  <condition>Cystic Fibrosis of the Adult</condition>
  <arm_group>
    <arm_group_label>Adults patients with chronic respiratory diseases</arm_group_label>
    <description>- 200 adult patients with chronic respiratory diseases will be studied longitudinally and transversely (follow-up: 6 months) in 12 centres.&#xD;
Sample 1 (n=110 patients) with COPD&#xD;
Sample 2 (n=30 patients) with Diffuse interstitial lung diseases&#xD;
Sample 3 (n=30 patients) with Pulmonary Arterial Hypertension primary or secondary (post embolic .....).&#xD;
Sample 4 (n=30 patients) Adult with Cystic fibrosis</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cross sectional psychometric evaluation of a self-administered dyspnea questionnaire.</intervention_name>
    <description>Evaluation will be performed on a group of 200 patients deriving from 4 samples.&#xD;
From these 200 patients, a sub-sample will be evaluated at 7 days (DYSLIM questionnaire only) for reproducibility (n = 50 patients: 10 patients with diffuse interstitial lung disease, 10 patients with cystic fibrosis, 10 patients with arterial pulmonary hypertension, 20 patients with COPD).&#xD;
From these 200 patients, a sub-sample (COPD, n = 60) will be recruited among patients undergoing pulmonary rehabilitation at the beginning of the 6 months separating follow up visit and the initial assessment.</description>
    <arm_group_label>Adults patients with chronic respiratory diseases</arm_group_label>
    <other_name>Self-administered dyspnea questionnaire</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Study Population are adults patients with chronic respiratory diseases (Sample1: COPD;&#xD;
        Sample 2: Diffuse interstitial lung diseases; Sample 3: Pulmonary Arterial Hypertension&#xD;
        primary or secondary (post embolic .....); Sample 4: Adult with Cystic fibrosis)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1) Sample1: COPD GOLD / ATS &gt; 2 without major co-morbidity&#xD;
&#xD;
               -  Sample 1A: n = 50: group of patients with no change in usual care and no acute&#xD;
                  event (evaluation of reproducibility)&#xD;
&#xD;
               -  Sample1B: n = 60: patients assessed before and after a qualifying period of&#xD;
                  pulmonary rehabilitation&#xD;
&#xD;
          -  2) Sample 2 (n = 30): diffuse interstitial lung diseases Criteria: Pulmonary Fibrosis:&#xD;
             Idiopathic or nonspecific interstitial lung diseases (NILD) according to international&#xD;
             criteria (ATS), sarcoidosis with parenchymal lesions (old classification stage II and&#xD;
             III), and exceptionally alveolar proteinosis.&#xD;
&#xD;
          -  3) Sample 3 (n = 30) primary or secondary arterial pulmonary hypertension (post&#xD;
             embolic .....).&#xD;
&#xD;
          -  4) Sample4 (n = 30): Adult with Cystic fibrosis.&#xD;
&#xD;
          -  5) patient with stable Status (no exacerbation for at least one month)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1) Patient under 18 years&#xD;
&#xD;
          -  2) Inability to fill in questionnaires&#xD;
&#xD;
          -  3) Other respiratory disease&#xD;
&#xD;
          -  4) left symptomatic heart failure&#xD;
&#xD;
          -  5) Obesity with a BMI&gt; 35 kg/m2&#xD;
&#xD;
          -  6) Inability to perform PFT (Pulmonary Function Testing)&#xD;
&#xD;
          -  7) Pregnant or breastfeeding woman&#xD;
&#xD;
          -  8) Patient unable to consent&#xD;
&#xD;
          -  9) Lack of social insurance coverage&#xD;
&#xD;
          -  10) Patient in exclusion period because of another protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thierry Perez, MD</last_name>
    <role>Study Chair</role>
    <affiliation>CHRU de Lille / Hôpital Calmette - France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nicolas ROCHE, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>APHP- Hopital Cochin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Service de Pneumologie AP-HP, Hôpitaux Universitaires Paris Centre</name>
      <address>
        <city>Paris</city>
        <zip>75006</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>August 29, 2014</study_first_submitted>
  <study_first_submitted_qc>August 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 3, 2014</study_first_posted>
  <last_update_submitted>July 31, 2017</last_update_submitted>
  <last_update_submitted_qc>July 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dyspnea</keyword>
  <keyword>Self-administered questionnaire</keyword>
  <keyword>Chronic respiratory disease</keyword>
  <keyword>COPD</keyword>
  <keyword>Diffuse interstitial lung diseases</keyword>
  <keyword>Pulmonary arterial hypertension</keyword>
  <keyword>Cystic fibrosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Pulmonary Arterial Hypertension</mesh_term>
    <mesh_term>Dyspnea</mesh_term>
    <mesh_term>Lung Diseases, Interstitial</mesh_term>
    <mesh_term>Respiration Disorders</mesh_term>
    <mesh_term>Respiratory Tract Diseases</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

